drugset / Trial / NCT07141199

A Study to Evaluate Adverse Events, How the Drug is Tolerated, and How the Drug Moves Through the Body of Intravenous Infusions of ABBV-8736 in Adult Healthy Volunteers

NCT07141199

Phase 1 Completed 24 enrolled AbbVie
RandomizedParallel-groupDouble-blindBasic science

Summary

The objective of this study is to assess the safety, tolerability, pharmacokinetics, and immunogenicity following multiple intravenous (IV) ascending doses of ABBV-8736 in healthy adult participants.

Timeline

Start
2025-09-02
Primary completion
2026-03-23
Completion
2026-03-23

Drugs

EvaluationDrugModalityDoseRoute
Subject ABBV-8736 Unknown Intravenous

Indications

No indication recorded.